Is 2.4mg of Wegovy a lot — and what does reaching that dose mean for you?

How 2.4mg fits into the decision to stay or step further

The Wegovy titration schedule exists for a practical reason: semaglutide's most common side effects are gastrointestinal, and slower escalation gives the body time to settle. Most patients begin on 0.25mg, a dose that does very little therapeutically but allows the digestive system to adjust. From there, the schedule moves through 0.5mg, 1mg and 1.7mg before arriving at 2.4mg. You can read more about what earlier points in that journey feel like on our page on the 1.7mg dose, which is the step immediately before this one.

At 2.4mg, the medicine is working at the level studied in the landmark STEP 1 trial, published in the New England Journal of Medicine, which found an average body-weight reduction of around 15% over 68 weeks. That figure comes from a defined maintenance dose, not from the titration period. The decision facing most people at this stage is not "is this too much?" but "is this working well enough, and how long do I stay here?"

The titration schedule is described factually in the full Wegovy dose guide; your prescriber decides the pace and timing for your situation specifically.

What the MHRA approval of 7.2mg means for how you read 2.4mg now

Context matters here. When Wegovy first launched in the UK, 2.4mg was the top of the licensed range. That changed in early 2026. The MHRA approved a 7.2mg maintenance dose, and by April 2026 a dedicated single-dose 7.2mg pen (one pre-set weekly injection) received its own approval for adults with a BMI of 30 or above. Trial data at that higher dose reported average weight loss of around 20.7% over 72 weeks, closing the gap with tirzepatide results seen in the SURMOUNT programme.

What that means practically is that 2.4mg is no longer the ceiling. For some people it will remain the right long-term dose; for others, a prescriber may judge that stepping to 7.2mg is appropriate. Neither decision is automatic. The 2.4mg page covers what to expect at this specific level in more detail, and the dedicated pen guide explains how the device itself works. The pen that arrives is a pre-filled auto-injector (discreet, plain-labelled packaging, tracked to your door by DPD) and the mechanism locks after use, which matters if you are new to self-injection.

The MHRA's announcement of the 7.2mg pen approval is publicly available if you want to read the regulator's own summary of the evidence behind it.

Side effects at 2.4mg: what changes compared with earlier doses

For many people, the transition from 1.7mg to 2.4mg brings a temporary return of nausea or digestive discomfort, the same pattern seen after earlier increases, just at a higher level. This is not a sign something has gone wrong. It tends to settle within one to two weeks as the body adjusts. Nausea, loose stools, constipation, indigestion and fatigue are the most commonly reported effects; they are typically mild to moderate and transient rather than persistent.

A smaller number of people find the 2.4mg dose harder to tolerate than the 1.7mg level. If that is your experience, the right step is to speak to your prescriber, not to reduce the dose on your own. Side effects that are severe, persistent, or include serious symptoms such as acute stomach pain radiating to the back need prompt medical attention; pancreatitis, while uncommon, is a recognised risk with GLP-1 medicines. You can report suspected side effects to the MHRA through the Yellow Card scheme. Tracking how you feel after each increase is genuinely useful information for your prescribing clinician.

If you are considering where the 1mg step sits in all of this, our 1mg dose explainer covers the earlier part of the journey.

The clinical question underneath "is this a lot?"

Most people asking this question are really asking one of two things: am I on a dose that is appropriate for me, or is there further to go if this is not enough? Both are reasonable questions, and both belong in a clinical conversation rather than a search results page.

Suitability for 2.4mg (and for Wegovy at all) depends on the full clinical picture: weight history, current BMI, any relevant conditions, other medicines, and how earlier doses have been tolerated. BMI alone does not settle it. Under the UK licence, Wegovy is available for adults with a BMI of 30 or above, or 27 to 29.9 alongside a weight-related condition such as hypertension or high cholesterol; the prescriber reviews whether those criteria are met and whether the benefit outweighs any individual risk. You can get a sense of the overall treatment landscape on the weight-loss treatment overview, which sets Wegovy alongside the other licensed options.

If you are thinking about the cost side of things (how much a private prescription at this dose typically runs) the Wegovy price guide sets out the honest picture, including what to expect from a legitimate provider. At nume, every repeat order is reviewed by a GPhC-registered prescriber before dispatch; the consultation is free, and there are no subscription traps. If you would like that clinical conversation, the straightforward next step is to start your free consultation.